{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044387","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.431478+00:00","generated_at":"2026-06-07T15:14:22.297434+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mangoceuticals enters licensing deal for Kyzatrex® testosterone capsules with Marius Pharmaceuticals","bullets":["Issued 100,000 restricted shares to Marius for non-exclusive license to market Kyzatrex® on MangoRx telehealth platform.","Two-year initial term; renews automatically if MangoRx maintains at least 2,500 monthly Kyzatrex patients.","Marius can terminate without cause on 60 days' notice, or if 30% of patient milestone not met within 6 months of launch by Jan 31, 2024.","MangoRx agrees not to market competing testosterone undecanoate products during term and 12 months after."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044387","json":"https://secwatch.observer/filing/0001493152-23-044387.json","markdown":"https://secwatch.observer/filing/0001493152-23-044387.md","text":"https://secwatch.observer/filing/0001493152-23-044387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/0001493152-23-044387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:14:22.297434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe706218cb701623eaa7833022cccb5600c2216e","claim":"MANGOCEUTICALS, INC. entered into Marius Agreement with Marius Pharmaceuticals, LLC valued at 100,000 shares of our restricted common stock (effective 2023-12-10).","evidence_excerpt":"On December 10, 2023, we entered into a Marketing Agreement with Marius Pharmaceuticals, LLC (“ Marius ”) allowing us the use of the trademark “Kyzatrex®” oral testosterone undecanoate softgel capsules","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/0001493152-23-044387-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Marius Pharmaceuticals, LLC"},{"label":"Value","value":"100,000 shares of our restricted common stock"},{"label":"Effective","value":"2023-12-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}